Although highly active retroviral therapy (HAART) dramatically reduces viral load and restores CD4 T-cell counts in HIV-infected individuals, its success is hampered by the fact that HIV can establish a latent proviral reservoir within long-lived resting memory CD4 lymphocytes. The molecular underpinnings of HIV latency involve multiple host factors and pathways actively repressing HIV transcription and maintaining the proviral genome in a transcriptionally inert state. Many host factors have been implicated based on genome-wide screens in cell-line based models of latency. But the exact role of these candidate genes in HIV latency occurring within resting primary CD4 T cells, remain unknown. The evaluation of these genes in resting primary CD4 T cells is hampered by the fact that shRNAs cannot be introduced into these cells using lentiviral vectors. In this collaboration among three CARE investigators (Warner C. Greene, Jonathan Karn, Vincente Planelles), we now propose to utilize a novel technology based on HIV-2 Vpx to render resting CD4 T cells permissive to lentivirus infection. This technology will permit efficient knockdown and evaluation of the candidate regulatory genes in resting primary CD4 T cells. This approach first involves pretreating cells with virion like particles (VLP) encapsulating Vpx to remove anti-viral reverse transcription block mediated by SAMHD1 followed by shRNA lentiviral transduction. A number of potential positive and negative regulators of HIV latency identified in CARE-sponsored studies will be systematically tested including the genome organizer and transcription repressor CTCF, select receptor subunits in the immunosuppressive PDCD1 and pro-inflammatory interleukin IL22RA pathways, and a putative Tat cofactor termed TRIM32. The evaluation of these cellular genes in primary CD4 T cell models of HIV latency formed in memory CD4 T cells, Th17 CD4 T cells and Treg CD4 T cells promises to provide key insights into the role of these genes in HIV latency. These studies could lay the foundation for finding small molecules that when combined will promote effective purging of the latent reservoir in patients while not producing a general state of cellular activation.

Public Health Relevance

Although highly active retroviral therapy (HAART) can dramatically extend the life expectancies of HIVinfected individuals, these drugs cannot cure patients because of the presence of a latent reservoir of druginsensitive virus. We propose testing the involvement of various gene candidates in primary CD4 T cells using a novel Vpx-based technology to introduce lentiviral encoded shRNAs into these cells. These studies promise to provide key insights into the molecular underpinnings of HIV latency that will inform the search for small molecule cocktails capable of effectively purging latent HIV proviruses.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Program--Cooperative Agreements (U19)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-JBS-A (M1))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of North Carolina Chapel Hill
Chapel Hill
United States
Zip Code
Honeycutt, Jenna B; Sheridan, Patricia A; Matsushima, Glenn K et al. (2015) Humanized mouse models for HIV-1 infection of the CNS. J Neurovirol 21:301-9
King, Helen L; Keller, Samuel B; Giancola, Michael A et al. (2014) Pre-exposure prophylaxis accessibility research and evaluation (PrEPARE Study). AIDS Behav 18:1722-5
Manson McManamy, Mary E; Hakre, Shweta; Verdin, Eric M et al. (2014) Therapy for latent HIV-1 infection: the role of histone deacetylase inhibitors. Antivir Chem Chemother 23:145-9
Spivak, Adam M; Andrade, Adriana; Eisele, Evelyn et al. (2014) A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy. Clin Infect Dis 58:883-90
Duverger, Alexandra; Wolschendorf, Frank; Anderson, Joshua C et al. (2014) Kinase control of latent HIV-1 infection: PIM-1 kinase as a major contributor to HIV-1 reactivation. J Virol 88:364-76
Denton, Paul W; Long, Julie M; Wietgrefe, Stephen W et al. (2014) Targeted cytotoxic therapy kills persisting HIV infected cells during ART. PLoS Pathog 10:e1003872
Abreu, Celina M; Price, Sarah L; Shirk, Erin N et al. (2014) Dual role of novel ingenol derivatives from Euphorbia tirucalli in HIV replication: inhibition of de novo infection and activation of viral LTR. PLoS One 9:e97257
Archin, Nancie M; Margolis, David M (2014) Emerging strategies to deplete the HIV reservoir. Curr Opin Infect Dis 27:29-35
Liu, Pingyang; Xiang, Yanhui; Fujinaga, Koh et al. (2014) Release of positive transcription elongation factor b (P-TEFb) from 7SK small nuclear ribonucleoprotein (snRNP) activates hexamethylene bisacetamide-inducible protein (HEXIM1) transcription. J Biol Chem 289:9918-25
Persaud, Deborah; Patel, Kunjal; Karalius, Brad et al. (2014) Influence of age at virologic control on peripheral blood human immunodeficiency virus reservoir size and serostatus in perinatally infected adolescents. JAMA Pediatr 168:1138-46

Showing the most recent 10 out of 77 publications